January 9, 2015

Teva Pharmaceuticals on Friday announced the launch of linezolid injection, the generic equvialent to Zyvox injection from C.P. Pharmaceuticals.

January 8, 2015

Camber Pharmaceuticals on Thursday announced the launch of valsartan tablets USP in 40-, 80-, 106- and 320-mg dosage strengths.

 

January 8, 2015

Sandoz may be on track to receive the first biosimilar drug approval from the Food and Drug Administration for its Zarxio.

January 7, 2015

Lupin Pharmaceuticals on Tuesday launched its valsartan tablets USP in 40-, 80-, 160- and 320-mg dosage strengths. The drug is the generic version Novartis's Diovan tablets.

January 7, 2015

Teva Pharmaceutical on Tuesday announced the Food and Drug Administration approved the launch of the company's valsartan tablets, the generic version of Diovan tablets from Novartis. 

 

January 6, 2015

Aurobindo Pharma on Tuesday announced that the company has received final approval from the U.S. Food & Drug Administration to manufacture and market Valsartan Tablets.

January 6, 2015

Vermont Attorney General Bill Sorrell is investigating generic drug price inflation.

January 5, 2015

Mylan announced the introduction of valsartan tablets USP in 40-, 80-, 160- and 320-mg dosage strengths. 

December 29, 2014

Telemedicine and a growing demand for biopharmaceutical medications were among the top trends in health care in 2014, according to Kalorama Information.

December 29, 2014

In a staff memo, the Office of Generics Drug’s acting director, Kathleen Uhl, vowed to take action on 90% of the abbreviated new drug application backlog before October 2017, and has appointed Ted Sherwood as acting director of OGD’s Office of Regulatory Operations to help with the improvements, FDANews.com has reported.

December 22, 2014

Mylan has announced the U.S. launch of its Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day and 0.1 mg/day (twice weekly), which is the generic version of Novartis' Vivelle-DOT.

December 22, 2014

Sandoz has announced the U.S. market introduction of estradiol transdermal system, an authorized generic version of Vivelle-Dot, which is marketed by Novartis Pharmaceuticals.

December 18, 2014

Dr. Reddy’s Laboratories announced Tuesday that it has launched Valganciclovir Tablets USP 450 mg, a therapeutic equivalent generic version of the antiviral Valcyte (Valganciclovir) tablets, in the U.S. market.

December 18, 2014

The U.S. Senate Special Committee on Aging unveiled a new bipartisan report earlier this week that focuses on ways to increase the use of generic drugs within the Medicare Part D program.

December 17, 2014

The Generic Pharmaceutical Association on Wednesday expressed concerns that the current structure of the Trans-Pacific Partnership agreement (TPP) will impede generic utilization.

December 16, 2014

Actavis on Tuesday announced the planned senior management team that will lead the global pharmaceutical company following the successful close of the acquisition of Allergan.

December 16, 2014

Dr. Reddy's Labs announced the launch of valganciclovir tablets USP in 450-mg strength. 

 

December 16, 2014

 Greenstone announced the launch of celecoxib — the authorized generic version of Pfizer's Celebrex — to its line of generic pharmaceuticals. 

December 16, 2014

Use of cigarettes, alcohol and abuse of prescription pain relievers among teens has declined since 2013, while marijuana use rates were stable, according to the 2014 Monitoring the Future survey, released Tuesday.

December 16, 2014

The flu continues to pick up in pockets of the Midwest and across the South, according to the latest Walgreens Flu Index report, a weekly report developed to provide state- and market-specific information regarding flu activity.

December 11, 2014

Lupin Pharmaceuticals launched the authorized generic version of Celebrex capsules in 50-, 100-, 200- and 400-mg dosage strengths. 

December 11, 2014

Mylan on Thursday announced the launch of methocarbamol injection USP, 100 mg. 

December 11, 2014

Mylan on Thursday announced the launch of prednisolone sodium phosphate orally disintegrating tablets in 10-mg, 15-mg and 30-mg dosage strengths. 

 

December 11, 2014

Teva Pharmaceuticals on Thursday announced the availability of levalbuterol inhalation solution, USP (concentrate), a generic equivalent to Xopenex inhalation solution concentrate.